Abbott Park News
-
Abbott Laboratories, the medical device and nutritional products maker that split off its drug unit on Jan. 1, said first-quarter profit rose 55 percent on higher sales of its baby formula and lower taxes.
-
AbbVie Inc., the drugmaker split off from Abbott Laboratories this year, will fire its sales force for heart drugs as the medicines lose patent protection and face generic competition, according to a person familiar with the matter.
-
As attacks on account secrecy and the fall from grace of Switzerland’s biggest banks leave Zurich mired in crisis management, another city an hour away is quietly moving ahead.
-
Abbott Laboratories needs to conduct more research on its proposed clamp for leaky heart valves before U.S. regulators can decide whether to approve the device, Food and Drug Administration staff said today.
-
Abbott Laboratories’ proposed clamp for leaky heart valves, a less-invasive option to open-chest surgery, may not be effective, U.S. regulatory advisers said.
-
The six biggest U.S. drugmakers avoided paying $7.05 billion in U.S. taxes last year by shifting their profits overseas. That’s almost double the amount they saved using the same strategy 10 years earlier, according to data compiled by Bloomberg.
-
On April 14, 2011, James Fan stood on a parking garage landing at Newark Liberty International Airport, a cheer-you-up letter from his young son in his pants pocket, the prospect of a four-story leap facing him.
-
Abbott Laboratories, the medical device and nutritional products maker, forecast 2013 earnings in line with analyst estimates after splitting off its drug business this month.
-
Johnson & Johnson won its challenge to two Abbott Laboratories patents on antibodies that help curb the effects of the painful skin disease psoriasis.
-
Abbott Laboratories, a U.S. health- care company, sued the German drug maker Boehringer AG’s Roxane Laboratories Inc. and accused it of infringing three patents for the HIV drug Norvir.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page